Literature DB >> 19254326

Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence.

D Micheloud1, M Salcedo, R Bañares, D Rincón, R Lorente, M A Muñoz-Fernández, S Resino.   

Abstract

This prospective study analyzed the relationship between several biological markers related to liver fibrosis at 3 months and 1 year post liver transplantation in 37 patients (19 with hepatitis C virus [HCV], 18 with alcoholic liver disease). Severe HCV recurrence (HCV-SR) was defined as fibrosis stage > or =F1 (METAVIR score) at 1 year and/or a value of hepatic venous pressure gradient > or=6 mmHg. We found HCV-SR patients had higher values of monocyte chemotactic protein-1 (MCP-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and hyaluronic acid (HA) than non-severe HCV recurrence patients (P<0.05). Moreover, receiver operating characteristic curve analysis showed that interferon-inducible protein 10 (IP-10) (area under the curve [AUC]: 0.74; confidence interval [CI] 95%: 0.49-0.91; P=0.043), MCP-1 (AUC: 0.78; CI 95%: 0.54-0.94; P=0.007), sVCAM-1 (AUC: 0.89; CI 95%: 0.67-0.98; P=0.005), and HA (AUC: 0.80; CI 95%: 0.55-0.94; P=0.035) have good predictive capacity for identifying severe HCV infection. The evaluation of these biomarkers may be useful in the early identification of patients in whom a more aggressive therapeutic approach could be necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254326     DOI: 10.1111/j.1399-3062.2009.00370.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  7 in total

1.  Fueling fibrosis in chronic hepatitis C.

Authors:  Ramon Bataller; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

2.  Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

Authors:  Ainhoa Fernández-Yunquera; Cristina Ripoll; Rafael Bañares; Marta Puerto; Diego Rincón; Ismael Yepes; Vega Catalina; Magdalena Salcedo
Journal:  World J Transplant       Date:  2014-06-24

Review 3.  Biomarkers in Transplantation--Proteomics and Metabolomics.

Authors:  Uwe Christians; Jelena Klawitter; Jost Klawitter
Journal:  Ther Drug Monit       Date:  2016-04       Impact factor: 3.681

Review 4.  Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus.

Authors:  A W Wahid Ansari; Reinhold E Schmidt; Esaki M Shankar; Adeeba Kamarulzaman
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

5.  Diagnostic Accuracy of Serum Hyaluronan for Detecting HCV Infection and Liver Fibrosis in Asymptomatic Blood Donors.

Authors:  Itatiana F Rodart; Madalena M Pares; Aline Mendes; Camila M Accardo; João R M Martins; Cleidenice B Silva; Fabrício O Carvalho; José A Barreto; Mitermayer G Reis; Ivarne L S Tersariol; Helena B Nader
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

6.  Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy.

Authors:  Truong Tam Nguyen; Reihani Niloofar; Pierre-Alain Rubbo; Kuster Nils; Karine Bollore; Jacques Ducos; Georges-Philippe Pageaux; Jacques Reynes; Philippe Van de Perre; Edouard Tuaillon
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-01-01       Impact factor: 2.576

Review 7.  Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.

Authors:  Ahmed Babiker; Mohamed Hassan; Safwan Muhammed; Gregory Taylor; Bhawna Poonia; Anoop Shah; Shashwatee Bagchi
Journal:  Clin Cardiol       Date:  2019-11-30       Impact factor: 2.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.